References for this Review were identified through searches of PubMed from 1950 to September, 2011, with the search terms “amyloidosis”, “familial amyloidosis”, “liver transplantation”, “apolipoprotein A-1”, and “gelsolin”. References were also identified from our own files. Only papers in English were reviewed. The final reference list was based on original publications and practical interest.
ReviewFamilial amyloid polyneuropathy
Introduction
Amyloidoses are a group of diseases characterised by tissue deposition of insoluble proteins and fibril aggregates oriented in a β-pleated sheet structure that form unbranched amyloid fibrils of 10–12 nm diameter. Amyloidosis can be acquired or hereditary. There are three main types of familial amyloid polyneuropathy (FAP), defined according to the precursor protein of amyloid: transthyretin (TTR), apolipoprotein A-1, and gelsolin. The main features of each type of FAP, and current approaches to diagnosis and treatment, are shown in the table.
TTR FAP is a life-threatening disease transmitted as an autosomal dominant trait. Nerve lesions are induced by deposits of fibril protein caused by mutated TTR (mTTR). TTR FAP typically causes a nerve length-dependent polyneuropathy that starts in the feet with loss of temperature and pain sensations, with autonomic dysfunction leading to death within 10 years on average. Apoliprotein A-1 amyloidosis, also known as the Iowa type, is characterised by the deposition of amyloid in major organs, including the kidneys, liver, and heart. Although a nerve length-dependent polyneuropathy can occur in apolipoprotein A-1 FAP, it is not a prominent feature of the disease. Gelsolin amyloidosis is characterised by cranial and peripheral sensory neuropathy, corneal lattice dystrophy, and cutis laxa. The course of gelsolin amyloid neuropathy is slow and quite benign.
In this Review, we describe the clinical manifestations and recent progress in the genetics and treatment of FAP, with special emphasis on TTR amyloidosis, which is by far the most common and devastating disease in this group.
Section snippets
TTR amyloidosis
Andrade first described FAP in north Portugal in 1952.1 The disease was subsequently reported in Japan (1968)2 and Sweden (1976).3 TTR was identified as the precursor of amyloid in this setting, and was found to be synthesised mainly by the liver.4 The most common pathogenic substitution, Val30Met, was then described and the TTR gene was fully sequenced in 1985.5 In 1990, liver transplantation was undertaken as a therapeutic approach for the treatment of FAP for the first time.6
Two main
Clinical aspects and diagnosis
Originally described in Iowa by van Allen and colleagues in 1969,74 apolipoprotein A-1 amyloidosis is characterised by polysystemic manifestations with onset in the fourth decade of life. The disease predominantly affects the kidney, liver, and gastrointestinal tract. A length-dependent polyneuropathy occurs but is not a prominent feature of the disease. Progression of renal lesions can lead to chronic renal failure, dialysis, and related polyneuropathy. Amyloid deposits, which strongly react
Gelsolin amyloidosis
Hereditary gelsolin amyloidosis (HGA) is an autosomal dominant systemic amyloidosis, first described in 1969 in Finland.80 HGA is characterised by adult onset of slowly progressive neurological deterioration, with corneal lattice dystrophy, cranial neuropathy, and cutis laxa. A mutation in the gelsolin gene leads to the generation of amyloid fibrils that are composed of fragments of gelsolin.81, 82 Most patients with HGA have been reported in Finland.83, 84 The estimated number of Finnish
Conclusion
FAP represents a heterogeneous group of autosomal dominant hereditary disorders characterised by tissue deposition of amyloid fibrils. The most common and by far the most severe form of FAP is caused by mutations in the TTR gene, which is responsible for the FAP that was originally reported in Portugal and that is found worldwide. Many mutations in the TTR gene have been identified, and progress has been made in diagnostic procedures and genetic counselling. Because TTR is secreted mainly by
Search strategy
References (96)
- et al.
Familial amyloid polyneuropathy: a clinico-pathologic study
J Neurol Sci
(2009) - et al.
Neurophysiological markers in familial amyloid polyneuropathy patients: early changes
Clin Neurophysiol
(2008) - et al.
Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M
Biochem Biophys Res Commun
(2000) - et al.
Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy
Neuromuscul Disord
(2009) - et al.
Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years
Am J Transplant
(2007) - et al.
Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients
Am J Transplant
(2007) - et al.
Selective silencing of a mutant transthyretin allele by small interfering RNAs
Biochem Biophys Res Commun
(2005) - et al.
Inosine(15.1) hammerhead ribozymes for targeting the transthyretin-30 mutation
Biochem Biophys Res Commun
(1999) - et al.
Suppression of transthyretin expression by ribozymes: a possible therapy for familial amyloidotic polyneuropathy
J Neurol Sci
(2001) - et al.
Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene
J Mol Diagn
(2009)
A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy
Genomics
Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I
J Mol Biol
Finnish hereditary amyloidosis: amino acid sequence homology between the amyloid fibril protein and human plasma gelsoline
FEBS Lett
Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene
FEBS Lett
A peculiar form of peripheral neuropathy: familial atypical generalized amyloidosis with special involvement of the peripheral nerves
Brain
Polyneuritic amyloidosis in a Japanese family
Arch Neurol
Familial amyloidosis with polyneuropathy. A clinical study based on patients living in northern Sweden
Acta Med Scand (Suppl)
Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy
Proc Natl Acad Sci USA
Structure of the chromosomal gene for human serum prealbumin
Gene
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30)
Clin Genet
Dissociated sensation in amyloidosis. Compound action potential, quantitative histologic and teased-fibre, and electron microscopic studies of sural nerve biopsies
Arch Neurol
Peripheral nerve changes in amyloid neuropathy
Brain
Length dependent degeneration of fibres in Portuguese amyloid polyneuropathy. A clinicopathological study
Neurology
Late-onset FAP type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features
Brain
Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity
Neurology
Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP)
Neurology
The significance of carpal tunnel syndrome in transthyretin Val30Met familial amyloid polyneuropathy
Amyloid
Familial oculoleptomeningeal amyloidosis
Brain
Transthyretin Leu12Pro is associated with systemic, neuropathic and leptomeningeal amyloidosis
Brain
Familial oculoleptomeningeal amyloidosis: report of a new family with unusual features
Arch Neurol
Oculoleptomeningeal amyloidosis associated with a new transthyretin variant Ser64
Arch Neurol
Myocardial hypertrophy and function are related to age at onset in familial amyloidotic polyneuropathy
Amyloid
Heart complications in familial transthyretin amyloidosis: impact of age and gender
Amyloid
Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up
Br J Ophthalmol
End-stage renal disease and dialysis in hereditary amyloidosis TTR V30M: presentation, survival and prognostic factors
Amyloid
Quantified sensory abnormalities in early genetically verified transthyretin amyloid polyneuropathy
Muscle Nerve
Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy
Muscle Nerve
Mass spectrometric-based proteomic analysis of amyloid neuropathy type in nerve tissue
Arch Neurol
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis
N Engl J Med
Transthyretin mutations in hyperthyroxinemia and amyloid diseases
Hum Mutat
Molecular mechanisms of amyloidosis
N Engl J Med
Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration
FEBS J
The molecular biology and clinical features of amyloid neuropathy
Muscle Nerve
Transthyretin-related familial amyloidotic polyneuropathy—progress in Kumamoto, Japan (1967–2010)
Proc Jpn Acad Ser B Phys Biol Sci
Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans
N Engl J Med
Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy
Neurology
Clinical and pathological findings of non-Val30Met TTR type familial amyloid polyneuropathy in Japan
Amyloid
Familial amyloidotic polyneuropathy in Sweden: a pedigree analysis
J Med Genet
Cited by (503)
Amyloidosis-history and development, emphasis on insulin and prion amyloids
2024, Brain DisordersPerioperative implications of amyloidosis and amyloid cardiomyopathy: A review for anesthesiologists
2024, Journal of Clinical AnesthesiaElectrocardiographic heterogeneity of patients with variant transthyretin amyloid cardiomyopathy: Genotype-phenotype correlations
2023, International Journal of Cardiology2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
2023, Journal of the American College of Cardiology